


Supplementary figure 1: Kaplan-Meier survival curves comparing post-NivoOS in patients who received or who did not receive CT after nivolumab progression in the group of patients eligible do post-nivolumab treatment



Patients at risk	115	49	17	3
Patients at risk	76	14	4	